Biopsy Bag Market to Reach US$ 2.65 Billion by 2033 | Astute Analytica
The market is on a strong upward trajectory, driven by the non-negotiable need for accurate cancer diagnosis and stringent infection control protocols. A clear industry-wide preference for disposable, secure, and easy-to-use products is shaping innovation.
Chicago, Sept. 09, 2025 (GLOBE NEWSWIRE) — The global biopsy bag market was valued at US$ 1.23 billion in 2024 and is expected to reach US$ 2.65 billion by 2033, growing at a CAGR of 8.9% during the forecast period 2025–2033.
The bedrock of demand for the biopsy bag market is the sheer volume of cancer diagnostic procedures performed annually across the globe. Globally, there were an estimated 20 million new cancer cases and 9.7 million deaths in 2022, the latest year for which comprehensive data is available. A figure of that magnitude translates to approximately 54,800 new cancer diagnoses and nearly 26,600 deaths occurring every single day worldwide. These statistics highlight the critical, high-volume nature of oncological diagnostics on an international scale.
Request Sample Pages: https://www.astuteanalytica.com/request-sample/biopsy-bag-market
Within specific cancer types, female breast cancer ranked as the most commonly diagnosed cancer globally, accounting for 2.3 million new cases. Lung cancer followed with 2.5 million new cases, making it the leading cause of cancer death. The need extends beyond adult populations; worldwide, it is estimated that over 400,000 children and adolescents are diagnosed with cancer each year. The unrelenting frequency of these diagnostic events across continents solidifies the essential and growing nature of the global biopsy bag market as a core component of the worldwide healthcare system.
Key Findings in Biopsy Bag Market
| Market Forecast (2033) | US$ 2.65 billion |
| CAGR | 8.9% |
| Largest Region (2024) | North America (38%) |
| By Product Type | Disposable biopsy bags (54%) |
| By Material | Polyethylene (54%) |
| By Closure Type | Zip Lock (62%) |
| By Application | Tumor Biopsy (42%) |
| By End Users | Hospitals (68%) |
| Top Drivers |
|
| Top Trends |
|
| Top Challenges |
|
Three Defining Aspects of Demand in the Global Biopsy Bag Market:
- The Procedural Shift to Ambulatory Surgical Centers (ASCs): The migration of biopsy procedures from traditional hospital outpatient departments to more cost-effective and specialized ASCs is fundamentally altering procurement volumes, logistics, and supply chain relationships.
- The Expansion of Precision Medicine and Companion Diagnostics: The growing reliance on genomic and biomarker testing requires higher-quality tissue samples, creating demand for specialized biopsy bags that ensure specimen integrity for complex, high-value analyses.
- Accelerated Adoption of Robotic-Assisted Biopsy Systems: The increasing use of robotic platforms for biopsies is standardizing procedural workflows, driving demand for uniform, system-compatible consumables, including biopsy bags designed for quick and error-free handling.
The Shift to Outpatient Settings Radically Alters Biopsy Bag Procurement
The accelerating migration of diagnostic procedures from hospitals to Ambulatory Surgical Centers (ASCs) is a primary force reshaping demand within the biopsy bag market. This trend is not speculative; it is quantified by the rapid growth of these facilities. In 2024, there were more than 6,400 Medicare-certified ASCs operating in the United States. Projections for 2025 show continued expansion, with the Centers for Medicare & Medicaid Services (CMS) finalizing a payment rate update of 3.0% for ASCs, encouraging further procedural migration. The scale of operations is significant, with over 30 million procedures now performed in ASCs annually.
The structural shift in the biopsy bag market directly impacts purchasing patterns. Unlike large hospitals with centralized procurement, the average ASC works with 15 different medical supply distributors to manage inventory. More than 2,000 ASCs are part of larger corporate chains, standardizing product choices across multiple locations. The procedures driving this shift are high-volume consumers of biopsy bags. Gastrointestinal (GI) endoscopy represents the largest single specialty in ASCs, with many of the 20 million endoscopies performed each year involving tissue sampling. Furthermore, there are over 7,500 physician owners of ASCs, giving clinicians direct influence over the selection of medical consumables. The total number of patient encounters in ASCs is expected to exceed 40 million in 2025, creating a massive, decentralized demand for biopsy bags.
Precision Medicine Creates Demand for High-Integrity Specimen Containment
The growth of personalized medicine is creating a powerful new demand vector for specialized, high-integrity products in the biopsy bag market. This is driven by the critical need to preserve tissue quality for companion diagnostics (CDx) and next-generation sequencing (NGS). As of early 2025, the U.S. FDA has approved more than 50 individual companion diagnostic devices. These tests are essential for modern oncology, with more than 300 unique biomarkers now used in clinical trials for cancer drug development. A single, widely used NGS test, FoundationOne CDx, analyzes 324 different cancer-related genes from a single tissue sample.
The value chain of genomic testing makes the biopsy bag a critical control point. A failed or contaminated sample can render a test costing between $2,000 and $5,000 useless. The tissue requirements are precise in the biopsy bag market ; NGS testing often requires a minimum of 10 unstained slides, all derived from the initial biopsied tissue. The number of clinical trials involving biomarkers has surged, with over 1,500 such trials active in early 2025. Investment in the sector is robust, with venture capital funding for precision oncology companies exceeding $3 billion in 2024. More than 400 clinical laboratories in the U.S. now offer complex genomic tumor testing, each representing a point of demand. The average turnaround time for these complex pathology reports is 10 days, a period during which sample integrity is paramount.
Manufacturing Economics Are Shaped by Polymer Costs and Essential Sterilization Processes
The production cost in the biopsy bag market is directly influenced by raw material pricing and capital-intensive manufacturing processes. The price of PVC resin, a polymer frequently used in medical applications, was approximately ₹68,500 per metric ton in mid-2025. For High-Density Polyethylene (HDPE), the price was recorded at ₹84,800 per metric ton. Polypropylene (PPHP Raffia grade), another key medical-grade plastic, was priced at ₹94,500 per metric ton. Beyond materials, sterilization is a critical and costly step.
The price of a 60-liter top-loading autoclave, essential for sterilizing medical equipment, can range from $18,000 to $40,000. For a larger, 150-liter front-loading autoclave, the cost increases to between $32,000 and $52,000. These investments are made within the context of global healthcare spending, which accounts for approximately 10% of the world’s GDP. The broader medical polymers sector, valued at $40.8 billion in 2024, is projected to reach $93.8 billion by 2035, indicating strong underlying growth. Within this sector, medical resins and fibers are the largest segment, holding a 75.21% share.
Laboratory Automation and Technological Innovation Redefine Product Feature Requirements
The modern laboratory is rapidly evolving, with automation creating new demands for compatible and intelligent consumables. The global lab automation market, a key influencer on the Biopsy bag market, is expected to be valued at approximately $2.5 billion in 2025. Looking ahead, a market projection suggests a value of $6.3 billion by 2035. Strategic collaborations are accelerating a trend. In January 2025, Agilent Technologies and ABB Robotics partnered to produce new automated laboratory solutions.
In March 2025, another strategic agreement was signed to provide transfusion medicine labs with new robotics and software. At least 17 distinct trends, led by automation and AI, are predicted to shape lab operations in 2025. Among them, machine learning-driven analytics are projected for increased adoption to guide decisions on equipment usage and maintenance. These advancements necessitate biopsy bags with features like barcode compatibility and designs that integrate seamlessly with robotic handling systems.
Navigating a Complex Web of Biohazard Safety and Regulatory Compliance Mandates
A stringent regulatory framework governs every aspect of biopsy specimen handling, from collection to disposal in the biopsy bag market . OSHA’s Bloodborne Pathogens standard (1910.1030) is the primary regulation governing biohazard waste practices in the U.S. The related standard for Personal Protective Equipment is detailed in 1910 Subpart I. Furthermore, OSHA’s standard 1910.145 specifies requirements for accident prevention signs, including the universal biohazard symbol. A broad mandate for worker safety is provided by the Occupational Safety and Health Act of 1970’s General Duty Clause. OSHA regulations define at least five specific categories of regulated medical waste that require specialized handling protocols.
The agency has also established at least four distinct levels of Personal Protective Equipment (PPE), from Level A to Level D, for handling hazardous materials. These comprehensive regulations create a strong driver within the Biopsy bag market for products that ensure containment, prevent leaks, and support compliance. Even proficiency testing records for labs must be retained for at least 2 years.
We Offer Customization on All Reports – Ask Now: https://www.astuteanalytica.com/report-walkthrough/biopsy-bag-market
The Significant and Geographically Variable Economics of Biohazard Waste Management
The disposal of used biopsy bags and other regulated medical waste represents a significant operational cost for all healthcare facilities across the biopsy bag market . The cost for medical waste removal services can range widely, from as low as $2 to as high as $20 per pound. For specific waste types, costs are more defined. Toxic or infectious substances, categorized as HAZMAT Class 6, can have disposal costs from $5 to $12 per pound. Flammable solids, or HAZMAT Class 4, typically cost between $0.80 and $3 per pound to dispose of.
Geography plays a major role in pricing. A medical facility in a large metropolitan area like Atlanta may pay between $20 to $45 per box for disposal. In sharp contrast, a facility in a rural location could pay between $75 to $200 per box for the same service, reflecting higher transportation costs. Most smaller facilities generate a predictable volume, typically around two boxes of medical waste each month.
Global Biopsy Bag Market Major Players:
- 3M Company
- Cardinal Health
- Thermo Fisher Scientific
- Medline Industries
- CANCER DIAGNOSTICS Inc
- Mortech Manufacturing
- Sakura
- Electron Microscopy Sciences
- Saati
- Simport
- Citotest
- CellPath
- Leica Biosystems Nussloch GmbH
- Other Prominent Players
Key Market Segmentation:
By Material Type
- Polypropylene
- Nylon
- PVC
- Polyethylene
- Others
By Product Type
- Standard Biopsy Bags
- Reusable Biopsy Bags
- Disposable Biopsy Bags
- Customized Biopsy Bags
- Others
By End Use
- Diagnostic Laboratories
- Research Institutes
- Hospitals
- Ambulatory Surgical Centers
- Others
By Closure Type
- Tie Closure
- Zip Lock
- Adhesive Seal
- Snap Lock
- Others
By Application
- Organ Biopsy
- Tumor Biopsy
- Bone Biopsy
- Soft Tissue Biopsy
- Others
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
- South America
Understand the Report in Depth – Schedule a Guided Walkthrough: https://www.astuteanalytica.com/report-walkthrough/biopsy-bag-market
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
